TY - JOUR
T1 - Current therapies for lowering lipoprotein (a)
AU - van Capelleveen, Julian C.
AU - van der Valk, Fleur M.
AU - Stroes, Erik S. G.
PY - 2016
Y1 - 2016
N2 - Lipoprotein (a) [Lp(a)] is a human plasma lipoprotein with unique structural and functional characteristics. Lp(a) is an assembly of two components: a central core with apoB and an additional glycoprotein, called apo(a). Ever since the strong association between elevated levels of Lp(a) and an increased risk for CVD was recognized, interest in the therapeutic modulation of Lp(a) levels has increased. Here, the past and present therapies aiming to lower Lp(a) levels will be reviewed, demonstrating that these agents have had varying degrees of success. The next challenge will be to prove that Lp(a) lowering also leads to cardiovascular benefit in patients with elevated Lp(a) levels. Therefore, highly specific and potent Lp(a)-lowering strategies are awaited urgently
AB - Lipoprotein (a) [Lp(a)] is a human plasma lipoprotein with unique structural and functional characteristics. Lp(a) is an assembly of two components: a central core with apoB and an additional glycoprotein, called apo(a). Ever since the strong association between elevated levels of Lp(a) and an increased risk for CVD was recognized, interest in the therapeutic modulation of Lp(a) levels has increased. Here, the past and present therapies aiming to lower Lp(a) levels will be reviewed, demonstrating that these agents have had varying degrees of success. The next challenge will be to prove that Lp(a) lowering also leads to cardiovascular benefit in patients with elevated Lp(a) levels. Therefore, highly specific and potent Lp(a)-lowering strategies are awaited urgently
U2 - https://doi.org/10.1194/jlr.R053066
DO - https://doi.org/10.1194/jlr.R053066
M3 - Review article
C2 - 26637277
SN - 0022-2275
VL - 57
SP - 1612
EP - 1618
JO - Journal of Lipid Research
JF - Journal of Lipid Research
IS - 9
ER -